Skip to main content
Year archive

BerGenBio — 2023 filings

All 120 regulatory filings released by BerGenBio (BGBIO) in 2023, sourced directly from the official regulator.

120 Filings
2023 Period
2023 filings (120)
Filing Released Lang
BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalized COVID-19 patients
Regulatory Filings
2023-12-15 English
BerGenBio to Present at DNB Nordic Healthcare Conference
Regulatory Filings
2023-12-12 English
BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting
Regulatory Filings
2023-12-11 English
BerGenBio ASA: Grant of share options
Director's Dealing
2023-12-08 English
BerGenBio ASA: Grant of share options
Share Issue/Capital Change
2023-12-08 English
BerGenBio ASA - New share capital registered
Share Issue/Capital Change
2023-12-08 English
BerGenBio ASA: Approval and publication of prospectus
Report Publication Announcement
2023-12-07 English
BerGenBio ASA - Updated timeline for delivery of new shares
Capital/Financing Update
2023-12-07 English
BerGenBio ASA - Final results for the first exercise period for warrants issued in connection with rights issue
Capital/Financing Update
2023-11-30 English
BerGenBio ASA - Preliminary results for the first exercise period for warrants issued in connection with rights issue
Share Issue/Capital Change
2023-11-29 English
BerGenBio ASA - Last day of the first exercise period for warrants issued in connection with rights issue
Share Issue/Capital Change
2023-11-28 English
BerGenBio ASA - Siste dag av den første utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen
Capital/Financing Update
2023-11-28 English
BerGenBio ASA - Information about the first exercise period for warrants issued in connection with rights issue
Share Issue/Capital Change
2023-11-24 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Director's Dealing
2023-11-21 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Director's Dealing
2023-11-21 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Director's Dealing
2023-11-21 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Director's Dealing
2023-11-21 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Director's Dealing
2023-11-21 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Director's Dealing
2023-11-21 English
BerGenBio ASA Mandatory notification of trade by primary insiders and close associates
Share Issue/Capital Change
2023-11-21 English
BerGenBio ASA - Start av den første utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen
Capital/Financing Update
2023-11-15 English
BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue
Capital/Financing Update
2023-11-15 English
BerGenBio ASA - Start av den første utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen
Capital/Financing Update
2023-11-15 Norwegian
BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue
Capital/Financing Update
2023-11-15 English
BerGenBio Reports Third Quarter 2023 Financial Results
Interim / Quarterly Report Q3 2023
2023-11-14 English
BerGenBio Reports Third Quarter 2023 Financial Results
Earnings Release Q3 2023
2023-11-14 English
Financial calendar
Report Publication Announcement
2023-11-13 English
BerGenBio ASA: Invitation to third quarter 2023 results webcast
Report Publication Announcement
2023-11-06 English
BerGenBio ASA: Invitation to third quarter 2023 results webcast
Report Publication Announcement
2023-11-06 English
BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
Regulatory Filings
2023-11-06 English
BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
Regulatory Filings
2023-11-06 English
BerGenBio Announces Poster Presentation at Upcoming ASH Meeting
Regulatory Filings
2023-11-02 English
BerGenBio Announces Poster Presentation at Upcoming ASH Meeting
Regulatory Filings
2023-11-02 English
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
Report Publication Announcement
2023-10-31 English
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
Legal Proceedings Report
2023-10-31 English
New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting
Regulatory Filings
2023-10-23 English
New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting
Regulatory Filings
2023-10-23 English
Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
Regulatory Filings
2023-10-16 English
Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
Regulatory Filings
2023-10-16 English
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
Investor Presentation
2023-09-11 English
Correction: BerGenBio ASA Seccond Quarter and half year 2023 Financial Report
Interim / Quarterly Report Q2 2023
2023-08-27 English
Correction: BerGenBio ASA Seccond Quarter and half year 2023 Financial Report
Report Publication Announcement
2023-08-27 English
BerGenBio Reports Second Quarter 2023 Financial Results
Interim / Quarterly Report Q2 2023
2023-08-23 English
BerGenBio Reports Second Quarter 2023 Financial Results
Earnings Release Q2 2023
2023-08-23 English
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
Investor Presentation
2023-08-22 English
BerGenBio ASA: Invitation to second quarter and half year 2023 results webcast
Report Publication Announcement
2023-08-16 English
BerGenBio ASA: Share capital increase registered
Share Issue/Capital Change
2023-06-29 English
BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission
Capital/Financing Update
2023-06-27 English
BerGenBio ASA - Information about the Warrants issued in connection with the Rights Issue
Share Issue/Capital Change
2023-06-23 English
BerGenBio ASA - Correction, new share capital and warrants registered
Share Issue/Capital Change
2023-06-22 English
BerGenBio ASA - New share capital and warrants registered
Share Issue/Capital Change
2023-06-22 English
BerGenBio Reports First Quarter 2023 Financial Results and Provides Business Update
Interim / Quarterly Report Q1 2023
2023-06-22 English
BerGenBio Reports First Quarter 2023 Financial Results and Provides Business Update
Earnings Release Q1 2023
2023-06-22 English
BerGenBio ASA - Updated timeline for delivery of Offer Shares and Warrants in connection with the Rights Issue
Capital/Financing Update
2023-06-19 English
BerGenBio ASA - Mandatory notification of trade, allocations to primary insiders and close associates in the Rights Issue
Director's Dealing
2023-06-15 English
BerGenBio ASA - Mandatory notification of trade, allocations to primary insiders and close associates in the Rights Issue
Director's Dealing
2023-06-15 English
BergenBio ASA - Disclosure of large shareholding
Major Shareholding Notification
2023-06-14 English
BerGenBio - Disclosure of large shareholding
Major Shareholding Notification
2023-06-14 English
BerGenBio ASA - Correction of final results of the Rights Issue
Capital/Financing Update
2023-06-14 English
BerGenBio ASA - Final results of the Rights Issue
Share Issue/Capital Change
2023-06-14 English
BerGenBio ASA - Preliminary results indicates an oversubscribed Rights Issue of gross NOK 250 million
Capital/Financing Update
2023-06-13 English
Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing
2023-06-13 English
Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing
2023-06-13 English
BerGenBio ASA - Last day of the Subscription Period in the Rights Issue
Report Publication Announcement
2023-06-13 English
Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing
2023-06-08 English
Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing
2023-06-08 English
Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing
2023-06-07 English
Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing
2023-06-07 English
BerGenBio ASA - Last day of trading in Subscription Rights
Share Issue/Capital Change
2023-06-07 English
BerGenBio - Disclosure of large shareholding
Major Shareholding Notification
2023-06-06 English
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO
Earnings Release Q2 2023
2023-06-05 English
BerGenBio to Participate in Investor Webcast and Q&A
Report Publication Announcement
2023-05-30 English
BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates
Director's Dealing
2023-05-30 English
BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates
Share Issue/Capital Change
2023-05-30 English
BerGenBio ASA - Commencement of the subscription period for the rights issue
Capital/Financing Update
2023-05-30 English
BerGenBio ASA - Commencement of the subscription period for the rights issue
Capital/Financing Update
2023-05-30 English
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue
Capital/Financing Update
2023-05-26 English
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue
Capital/Financing Update
2023-05-26 English
Shareholder disclosure
Major Shareholding Notification
2023-05-25 English
Shareholder disclosure
Report Publication Announcement
2023-05-25 English
BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
Regulatory Filings
2023-05-25 English
Mandatory notification of trade by related party to Primary Insiders
Director's Dealing
2023-05-24 English
Mandatory notification of trade by related party to Primary Insiders
Director's Dealing
2023-05-24 English
Mandatory notification of trade by related party to Primary Insiders
Director's Dealing
2023-05-24 English
BGBIO - Ex. subscription rights today
Share Issue/Capital Change
2023-05-23 English
BerGenBio ASA: Annual general meeting held
AGM Information
2023-05-22 Norwegian
BerGenBio ASA: Annual general meeting held
AGM Information
2023-05-22 English
BerGenBio ASA - Updated key information relating to the preferential rights issue
Capital/Financing Update
2023-05-20 English
BERGENBIO ASA - Terms of the partially underwritten rights issue
Capital/Financing Update
2023-05-20 English
Financial calendar
Report Publication Announcement
2023-05-09 English
BerGenBio to hold business update conference call
Call Transcript
2023-05-09 English
BERGENBIO ASA: Notice of Annual General Meeting
AGM Information
2023-04-28 Norwegian
BERGENBIO ASA: Notice of Annual General Meeting
AGM Information
2023-04-28 Norwegian
BERGENBIO ASA: Notice of Annual General Meeting
AGM Information
2023-04-28 English
BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022
Annual Report (ESEF) FY 2022
2023-04-28 English
BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022
Annual Report FY 2022
2023-04-28 English
BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022
Report Publication Announcement
2023-04-28 English
BerGenBio ASA - Key information relating to the preferential rights issue
Capital/Financing Update
2023-04-25 English
BerGenBio ASA - Key information relating to the preferential rights issue
Capital/Financing Update
2023-04-25 English
Financial calendar
Report Publication Announcement
2023-04-25 English
BerGenBio ASA: Proposed partially underwritten rights issue
Capital/Financing Update
2023-04-25 English
BerGenBio ASA: Foreslår delvis garantert fortrinnsrettsemisjon
Capital/Financing Update
2023-04-25 Norwegian
BerGenBio ASA: Proposed partially underwritten rights issue
Capital/Financing Update
2023-04-25 English
BerGenBio ASA: Foreslår delvis garantert fortrinnsrettsemisjon
Share Issue/Capital Change
2023-04-25 Norwegian
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
Regulatory Filings
2023-04-18 English
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
Regulatory Filings
2023-04-18 English
Financial calendar
Report Publication Announcement
2023-03-29 English
BerGenBio to Present at Upcoming Scientific Conferences
Report Publication Announcement
2023-03-28 English
BerGenBio to Present at the Carnegie Nordic Healthcare Conference
Report Publication Announcement
2023-03-16 English
BerGenBio to Present at the Carnegie Nordic Healthcare Conference
Regulatory Filings
2023-03-16 English
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
Regulatory Filings
2023-03-09 English
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
Regulatory Filings
2023-03-09 English
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Interim / Quarterly Report Q4 2022
2023-02-16 English
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Earnings Release Q4 2022
2023-02-16 English
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
Earnings Release Q4 2022
2023-02-15 English
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
Earnings Release Q4 2022
2023-02-15 English
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board
Board/Management Information
2023-02-02 English
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board
Board/Management Information
2023-02-02 English
BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
Report Publication Announcement
2023-02-01 English
BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
Report Publication Announcement
2023-02-01 English